Sarepta faces earnings test as ELEVIDYS slows, siRNA pipeline builds

Sarepta is expected to report Q1 EPS of $0.99 on revenue of $474.3 million, a sharp improvement from a $3.58 per-share loss in Q4, but revenue is still projected to fall 36% year over year. Investors are focused on ELEVIDYS, which saw preliminary Q4 revenue drop to $110 million from $132 million amid prior safety concerns, offset by early optimism around the siRNA pipeline and Japan launch. Analysts are split, with consensus at Hold and a $21.78 target, essentially in line with the $21.79 share price.

Analysis

SRPT is in a classic “prove-it” window where the stock will trade less on headline quarterly beats and more on whether management can stabilize the revenue base before the market re-prices the entire gene-therapy franchise downward. The key second-order effect is that any renewed friction around the core asset doesn’t just hit near-term sales; it lowers the probability that the pipeline gets valued as a clean platform, because investors will apply a higher discount rate to every follow-on program until safety/commercial execution is de-risked.

The more interesting setup is the asymmetry between the current implied valuation and the potential duration of the reset. If the core product continues to decelerate, consensus likely needs another multi-quarter reset, not just a one-quarter miss, which means the stock can remain range-bound or drift lower even on decent operating prints. Conversely, a genuinely clean update on tolerability, reimbursement durability, or Japan contribution could force short covering because positioning is likely built around skepticism rather than outright capitulation.

The contrarian angle is that the market may be underestimating optionality from pipeline data quality relative to the current core-business narrative. In small-cap biotech, a credible biomarker story with repeatable dosing signals can matter more than near-term revenue math if it broadens the addressable investor base from commercial-risk skeptics to platform-value buyers. That said, the burden of proof is high: until there is evidence the commercial slowdown has bottomed, any rally is likely to be sold into unless the company can show a faster-than-expected inflection in demand or a concrete catalyst within the next 1-2 quarters.

Competitively, the larger risk is that rivals use SRPT’s execution issues to reset physician and payer expectations around the category, which can extend the recovery period beyond the immediate earnings cycle. That makes this less of a single-quarter event and more of a 3-6 month trade around confidence restoration versus ongoing multiple compression.

Key Decisions for Investors

• Avoid initiating fresh long exposure ahead of earnings; if you want optionality, use SRPT call spreads into the print with 2-4 week tenor to express a catalyst-driven upside view while capping premium risk.
• For event-driven shorts, consider a small SRPT short or put spread into the release, sized for a 1-2 quarter reset risk rather than a binary blow-up; the best risk/reward is if guidance implies no near-term stabilization.
• Pair trade idea: long a diversified rare-disease/biotech basket vs short SRPT for 1-3 months, expressing the view that platform risk is being over-penalized in peers while SRPT remains a specific execution/safety overhang.
• If the company reports a clean quarter plus improved commentary on pipeline tolerability, cover shorts quickly: the stock could re-rate sharply over 5-15% in days on modestly positive surprises because positioning is likely defensive.
• Watch for a post-earnings entry only after the market confirms whether revenue erosion is slowing; a base-building trade is more attractive than catching the first reflex bounce.